Pretreatment Modified Albumin–Bilirubin Grade Is an Important Predictive Factor Associated with the Therapeutic Response and the Continuation of Atezolizumab plus Bevacizumab Combination Therapy for Patients with Unresectable Hepatocellular Carcinoma

Pretreatment Modified Albumin–Bilirubin Grade Is an Important Predictive Factor Associated with the Therapeutic Response and the Continuation of Atezolizumab plus Bevacizumab Combination Therapy for Patients with Unresectable Hepatocellular Carcinoma

Background: Atezolizumab plus bevacizumab (ATZ + BV) treatment is recommended as the first-line systemic therapy for patients with unresectable hepatocellular carcinoma (u-HCC). This study aimed to investigate the predictive factors of therapeutic response and the continuation of ATZ + BV treatment...

Full description

Bibliographic Details
Main Authors: Takashi Tanaka, Kazuhide Takata, Keiji Yokoyama, Hiromi Fukuda, Ryo Yamauchi, Atsushi Fukunaga, Satoshi Shakado, Shotaro Sakisaka, Fumihito Hirai
Format: Article
Language:English
Published: MDPI AG 2022-07-01
Series:Current Oncology
Subjects:
hepatocellular carcinoma
atezolizumab
bevacizumab
immune checkpoint inhibitors
adverse events
Online Access:https://www.mdpi.com/1718-7729/29/7/381

Internet

https://www.mdpi.com/1718-7729/29/7/381

Similar Items